PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibroste ...

A $3 billion agreement with Regeneron will expand biopharmaceutical production in North Carolina, creating 1,400 jobs by 2031 ...

Paper manufacturing stands at a critical juncture where environmental responsibility intersects with operational efficiency. The industry’s energy-intensive processes—pulping, pressing, drying, ...

A horrifying immigration raid at a high school in Minnesota has caused the entire school district to cancel class.

Akadeum Life Sciences, the leader in buoyant microbubble cell separation, today announced that its Chief Executive Officer ...

Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...

Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced today that ...

President Trump is planning on having the U.S. control Venezuela for years.

Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline ...

Before Kaela Martin completed the Front Line Advanced Supervisor course at Berkshire Community College, she had already made ...

Deep within a biosphere in the Ecuadorian Amazon is a luxury sanctuary that offers a fully guided immersion into the ...